NCT07012057View on ClinicalTrials.gov

Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

March 30, 2028

Study Completion Date

March 30, 2029

Conditions
MyositisDermatomyositis
Interventions
DRUG

Deucravacitinb

Participants will receive a 6mg pill taken 2 times per day over 24 weeks and an optional extension period

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH